Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.320 USD | -4.92% |
|
-11.79% | -90.81% |
25/06 | Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment | MT |
11/06 | Jaguar Health Establishes First Site for Canalevia-CA1 Field Study | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -33.6 | -50.82 | -42.71 | -43.17 | -36.99 | |||||
Return on Total Capital | -43.27 | -65.45 | -57.59 | -56.18 | -44.05 | |||||
Return On Equity % | -179.03 | -362.07 | -922.07 | -2.37T | -565.74 | |||||
Return on Common Equity | -295.44 | -365.11 | -866.42 | -1.92T | -628.65 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 65.05 | 46.18 | 83.11 | 79.13 | 83.27 | |||||
SG&A Margin | 223.72 | 599.7 | 223.36 | 236.12 | 205.52 | |||||
EBITDA Margin % | -208.6 | -861.71 | -271.28 | -326.88 | -247.51 | |||||
EBITA Margin % | -208.89 | -862.15 | -272.79 | -327.02 | -247.51 | |||||
EBIT Margin % | -227 | -901.36 | -287.85 | -347.51 | -263.76 | |||||
Income From Continuing Operations Margin % | -360.24 | -1.21T | -404.78 | -429.27 | -335.79 | |||||
Net Income Margin % | -360.24 | -1.21T | -396.91 | -423.11 | -329.3 | |||||
Net Avail. For Common Margin % | -411.81 | -1.21T | -396.91 | -423.11 | -329.3 | |||||
Normalized Net Income Margin | -177.16 | -723.95 | -233.68 | -283.43 | -210.04 | |||||
Levered Free Cash Flow Margin | -94.09 | -410.18 | -137.91 | -175.75 | -166.56 | |||||
Unlevered Free Cash Flow Margin | -103.94 | -408.06 | -169.74 | -270.18 | -167.67 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.24 | 0.09 | 0.24 | 0.2 | 0.22 | |||||
Fixed Assets Turnover | 13.53 | 3.6 | 6.97 | 5.79 | 7.61 | |||||
Receivables Turnover (Average Receivables) | 4.95 | 2.28 | 6.66 | 5.08 | 6.69 | |||||
Inventory Turnover (Average Inventory) | 1.34 | 0.61 | 0.34 | 0.25 | 0.2 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.35 | 1.84 | 0.74 | 2 | 1.63 | |||||
Quick Ratio | 0.77 | 1.24 | 0.26 | 0.62 | 0.49 | |||||
Operating Cash Flow to Current Liabilities | -1.16 | -2.26 | -1.09 | -2.38 | -1.49 | |||||
Days Sales Outstanding (Average Receivables) | 73.9 | 160.27 | 54.77 | 71.91 | 54.7 | |||||
Days Outstanding Inventory (Average Inventory) | 274 | 600.93 | 1.08T | 1.45T | 1.83T | |||||
Average Days Payable Outstanding | 470.46 | 397.23 | 472.97 | 468.28 | 603.53 | |||||
Cash Conversion Cycle (Average Days) | -122.56 | 363.97 | 659.63 | 1.06T | 1.28T | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 94.23 | 247.74 | -2.57T | 757.48 | 406.79 | |||||
Total Debt / Total Capital | 48.52 | 71.24 | 104.05 | 88.34 | 80.27 | |||||
LT Debt/Equity | 72.21 | 218.86 | -1.36T | 650.99 | 269.4 | |||||
Long-Term Debt / Total Capital | 37.18 | 62.94 | 55.17 | 75.92 | 53.16 | |||||
Total Liabilities / Total Assets | 59.85 | 77.75 | 102.86 | 90.35 | 83.19 | |||||
EBIT / Interest Expense | -7.63 | -4.64 | -2.7 | -5.31 | -133.47 | |||||
EBITDA / Interest Expense | -6.81 | -4.4 | -2.5 | -4.86 | -121.71 | |||||
(EBITDA - Capex) / Interest Expense | -6.82 | -4.4 | -2.51 | -4.86 | -121.77 | |||||
Total Debt / EBITDA | -0.85 | -0.79 | -1.1 | -1.2 | -1.3 | |||||
Net Debt / EBITDA | -0.43 | -0.33 | -0.92 | -0.99 | -1.01 | |||||
Total Debt / (EBITDA - Capex) | -0.85 | -0.79 | -1.09 | -1.2 | -1.3 | |||||
Net Debt / (EBITDA - Capex) | -0.43 | -0.33 | -0.92 | -0.99 | -1.01 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 62.51 | -53.81 | 175.8 | -18.36 | 19.75 | |||||
Gross Profit, 1 Yr. Growth % | 211.64 | -67.83 | 396.35 | -22.27 | 26.02 | |||||
EBITDA, 1 Yr. Growth % | -13.23 | 102.37 | -13.17 | -1.62 | -9.33 | |||||
EBITA, 1 Yr. Growth % | -13.25 | 102.17 | -12.73 | -2.13 | -9.36 | |||||
EBIT, 1 Yr. Growth % | -12.33 | 93.57 | -11.92 | -1.44 | -9.11 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -12.27 | 55.58 | -7.99 | -13.42 | -6.32 | |||||
Net Income, 1 Yr. Growth % | -12.27 | 55.58 | -9.77 | -12.97 | -6.8 | |||||
Normalized Net Income, 1 Yr. Growth % | -8.08 | 97.04 | -10.96 | -0.98 | -11.26 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | - | - | -95.12 | |||||
Accounts Receivable, 1 Yr. Growth % | 24 | -18.54 | 9.95 | 4.68 | -22.37 | |||||
Inventory, 1 Yr. Growth % | 30.67 | 76.13 | 43.35 | 30.82 | 12.58 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.65 | 156.13 | -2.13 | -1.47 | -16.27 | |||||
Total Assets, 1 Yr. Growth % | 17.67 | 24.33 | -10.91 | 6.98 | 5.24 | |||||
Tangible Book Value, 1 Yr. Growth % | -58.18 | 54.73 | 109.2 | -34.38 | -26.14 | |||||
Common Equity, 1 Yr. Growth % | 91.97 | -32.5 | -105.66 | -855.1 | 46.85 | |||||
Cash From Operations, 1 Yr. Growth % | -25.32 | 128.89 | -5.34 | 0.42 | -11.61 | |||||
Capital Expenditures, 1 Yr. Growth % | - | -14.29 | 1.18T | - | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -21.84 | 118.68 | -7.27 | 4.04 | 13.49 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -24.22 | 95.33 | 14.73 | 29.95 | -25.68 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 45.78 | -13.36 | 12.87 | 50.06 | -1.12 | |||||
Gross Profit, 2 Yr. CAGR % | 31.99 | 1.09 | 26.37 | 96.42 | -1.03 | |||||
EBITDA, 2 Yr. CAGR % | -10.23 | 28.67 | 32.56 | -7.58 | -5.55 | |||||
EBITA, 2 Yr. CAGR % | -9.48 | 28.6 | 32.83 | -7.58 | -5.82 | |||||
EBIT, 2 Yr. CAGR % | -8.8 | 26.81 | 30.57 | -6.83 | -5.35 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.55 | 16.83 | 19.64 | -10.75 | -9.94 | |||||
Net Income, 2 Yr. CAGR % | 2.55 | 16.83 | 18.47 | -11.39 | -9.94 | |||||
Normalized Net Income, 2 Yr. CAGR % | -2.32 | 31.72 | 32.44 | -6.1 | -6.26 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | - | - | |||||
Accounts Receivable, 2 Yr. CAGR % | 45.16 | 0.5 | -5.36 | 7.28 | -9.85 | |||||
Inventory, 2 Yr. CAGR % | -8.76 | 51.71 | 58.9 | 36.94 | 21.36 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -5.66 | 56.28 | 58.32 | -1.8 | -9.17 | |||||
Total Assets, 2 Yr. CAGR % | 2.17 | 20.95 | 5.24 | -2.38 | 6.11 | |||||
Tangible Book Value, 2 Yr. CAGR % | -47.94 | -19.56 | 79.92 | 17.16 | -30.38 | |||||
Common Equity, 2 Yr. CAGR % | 78.76 | 13.83 | -80.46 | -34.63 | 232.99 | |||||
Cash From Operations, 2 Yr. CAGR % | -18.02 | 30.75 | 47.2 | -2.5 | -5.79 | |||||
Capital Expenditures, 2 Yr. CAGR % | 3.56 | - | 231.66 | - | -54.42 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -22.77 | 25.46 | 42.4 | -1.78 | 8.67 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -17.57 | 17.23 | 49.7 | 22.1 | -1.73 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 29.1 | -0.62 | 27.45 | 1.32 | 39.19 | |||||
Gross Profit, 3 Yr. CAGR % | 97.82 | -17.02 | 71.82 | 7.47 | 69.41 | |||||
EBITDA, 3 Yr. CAGR % | 20.71 | 15.42 | 12.86 | 20.01 | -8.17 | |||||
EBITA, 3 Yr. CAGR % | 19.26 | 16.03 | 13.01 | 19.97 | -8.18 | |||||
EBIT, 3 Yr. CAGR % | 22.58 | 15.12 | 12.3 | 18.89 | -7.59 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 15.45 | 17.84 | 7.89 | 7.41 | -9.3 | |||||
Net Income, 3 Yr. CAGR % | 15.45 | 17.84 | 7.18 | 6.9 | -9.88 | |||||
Normalized Net Income, 3 Yr. CAGR % | 30.42 | 21.67 | 15.6 | 20.21 | -7.85 | |||||
Accounts Receivable, 3 Yr. CAGR % | 64.93 | 19.73 | 3.56 | -2.13 | -3.68 | |||||
Inventory, 3 Yr. CAGR % | 10.31 | 13.6 | 48.87 | 48.93 | 28.29 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -17.87 | 31.61 | 33.7 | 35.17 | -6.88 | |||||
Total Assets, 3 Yr. CAGR % | -0.6 | 9.08 | 9.23 | 5.82 | 0.1 | |||||
Tangible Book Value, 3 Yr. CAGR % | -30.6 | -25.15 | 10.62 | 28.54 | 0.46 | |||||
Common Equity, 3 Yr. CAGR % | -0.11 | 29.2 | -58.15 | -33.93 | -14.39 | |||||
Cash From Operations, 3 Yr. CAGR % | 15.85 | 15.44 | 17.4 | 29.58 | -5.64 | |||||
Capital Expenditures, 3 Yr. CAGR % | - | -2.77 | - | - | 38.67 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 186.5 | 6.3 | 13.43 | 28.26 | 3.07 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 163.84 | 7.2 | 16.39 | 42.8 | 3.48 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 88.83 | 98.26 | 22.35 | 17.19 | 15.14 | |||||
Gross Profit, 5 Yr. CAGR % | 95.09 | -22.41 | 65.99 | 17.12 | 37.8 | |||||
EBITDA, 5 Yr. CAGR % | - | 22.68 | 23.85 | 5.6 | 5.1 | |||||
EBITA, 5 Yr. CAGR % | 36.92 | 22.62 | 23.06 | 5.93 | 5.06 | |||||
EBIT, 5 Yr. CAGR % | 39.21 | 23.72 | 24.37 | 5.78 | 4.88 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 47.13 | 28.98 | 17.11 | 5.44 | 0.37 | |||||
Net Income, 5 Yr. CAGR % | 44.81 | 28.98 | 16.65 | 5.14 | -0.02 | |||||
Normalized Net Income, 5 Yr. CAGR % | 12.66 | 28.16 | 30.1 | 9.69 | 6.3 | |||||
Accounts Receivable, 5 Yr. CAGR % | 77 | 221.66 | 32.07 | 14.59 | -2.03 | |||||
Inventory, 5 Yr. CAGR % | - | 64.02 | 27.65 | 22.42 | 37.19 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 14.37 | 6.79 | 17.06 | 14.54 | |||||
Total Assets, 5 Yr. CAGR % | 41.98 | 71.76 | 1.69 | 4.34 | 7.97 | |||||
Tangible Book Value, 5 Yr. CAGR % | -28.62 | 35.09 | 1.59 | -10.46 | -8.09 | |||||
Common Equity, 5 Yr. CAGR % | -14.88 | 36.46 | -47.99 | -1.62 | -4.06 | |||||
Cash From Operations, 5 Yr. CAGR % | 73.92 | 19.39 | 27.5 | 7.9 | 7.51 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | -43.5 | - | - | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 8.1 | 113.07 | 2.99 | 11.5 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 8.18 | 107.22 | 12.93 | 8.77 |
- Stock Market
- Equities
- JAGX Stock
- Financials Jaguar Health, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition